{"title":"Virtual Cardiology: Past, Present, Future Directions, and Considerations.","authors":"Gauranga Mahalwar, Ashish Kumar, Ankur Kalra","doi":"10.1007/s12170-023-00719-0","DOIUrl":"10.1007/s12170-023-00719-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Through this review, we attempt to explore the role of telemedicine and virtual visits in the field of cardiology pre-COVID-19 and during COVID-19 pandemic, their limitations and their future scope for delivery of care.</p><p><strong>Recent findings: </strong>Telemedicine, which rose to prominence during COVID-19 pandemic, helped not only in reducing the burden on the healthcare system during a time of crisis but also in improving patient outcomes. Patients and physicians also favored virtual visits when feasible. Virtual visits were found to have the potential to be continued beyond the pandemic and play a significant role in patient care alongside conventional face-to-face visits.</p><p><strong>Summary: </strong>Although tele-cardiology has proven beneficial in terms of patient care, convenience, and access, it comes with its fair share of limitations-both logistical and medical. Whilst there remains a great scope for improvement in the quality of patient care provided through telemedicine, it has shown the potential to become an integral part of medical practice in the future.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12170-023-00719-0.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"17 6","pages":"117-122"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9993513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Futyma, Łukasz Zarębski, Shaojie Chen, A. Enriquez, H. Pürerfellner, P. Santangeli
{"title":"Risk Assessment and Management of Outflow Tract Arrhythmias Refractory to Prior Treatments","authors":"P. Futyma, Łukasz Zarębski, Shaojie Chen, A. Enriquez, H. Pürerfellner, P. Santangeli","doi":"10.1007/s12170-022-00712-z","DOIUrl":"https://doi.org/10.1007/s12170-022-00712-z","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"17 1","pages":"21-26"},"PeriodicalIF":1.9,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49561185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julio C Nunes, Shayena Shah, M. Fazal, Sofia E. Gomez, Chen Wei, Paul J. Wang, R. Stafford, T. Baykaner
{"title":"Patient Education Strategies to Improve Risk of Stroke in Patients with Atrial Fibrillation","authors":"Julio C Nunes, Shayena Shah, M. Fazal, Sofia E. Gomez, Chen Wei, Paul J. Wang, R. Stafford, T. Baykaner","doi":"10.1007/s12170-022-00709-8","DOIUrl":"https://doi.org/10.1007/s12170-022-00709-8","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"249-258"},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48227467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Applying Interventions to Address the Social Determinants of Health and Reduce Health Disparities in Congenital Heart Disease Patients","authors":"Bianca Cherestal, Z. Hudson, Keila N. Lopez","doi":"10.1007/s12170-022-00710-1","DOIUrl":"https://doi.org/10.1007/s12170-022-00710-1","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41927887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cheryl L. Woods-Giscombe, Jamie Conklin, Adam Dodd, Louise F. Barthold, Yvonne Perry, J. Brooks, Andrew Bradford, Sierra Vines, Raven Smith, E. Ikharo, Erum Agha, Aisha Chilcoat, Karen Sheffield-Abdullah, S. Gaylord
{"title":"Workplace Meditation Interventions for Reducing Psychological Stress and Other Cardiovascular Risk Factors: Workplace Wellness Policy Implications","authors":"Cheryl L. Woods-Giscombe, Jamie Conklin, Adam Dodd, Louise F. Barthold, Yvonne Perry, J. Brooks, Andrew Bradford, Sierra Vines, Raven Smith, E. Ikharo, Erum Agha, Aisha Chilcoat, Karen Sheffield-Abdullah, S. Gaylord","doi":"10.1007/s12170-022-00708-9","DOIUrl":"https://doi.org/10.1007/s12170-022-00708-9","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43734631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Wilkie, Ekaterina Skaritanov, Micaela Tobin, Angela Essa, A. Gubala, L. Ferraro, Lara C Kovell
{"title":"Hypertension in Women: Impact of Contraception, Fertility, and Hormone Treatment","authors":"G. Wilkie, Ekaterina Skaritanov, Micaela Tobin, Angela Essa, A. Gubala, L. Ferraro, Lara C Kovell","doi":"10.1007/s12170-022-00705-y","DOIUrl":"https://doi.org/10.1007/s12170-022-00705-y","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48915527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Atrial Fibrillation in Women: from Epidemiology to Treatment","authors":"K. Tamirisa, C. Dye, I. Ekeruo, A. Volgman","doi":"10.1007/s12170-022-00707-w","DOIUrl":"https://doi.org/10.1007/s12170-022-00707-w","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"1 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41801256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sean Paul Gaine, Renato Quispe, Jaideep Patel, Erin D Michos
{"title":"New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.","authors":"Sean Paul Gaine, Renato Quispe, Jaideep Patel, Erin D Michos","doi":"10.1007/s12170-022-00694-y","DOIUrl":"10.1007/s12170-022-00694-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>The primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein-cholesterol (LDL-C) lowering. Typically, statin therapy remains the first line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the U.S. Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD risk, as well as new therapies in the pipeline.</p><p><strong>Recent findings: </strong>Novel lipid therapies aim to lower risk of ASCVD by targeting reduction of atherogenic compounds, such as LDL, lipoprotein(a) (Lp(a)), and triglyceride-rich lipoproteins. Evolocumab and alirocumab, monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors which lower LDL-C by approximately 60%, have emerged as important therapies for use in patients with ASCVD as well as familial hypercholesterolemia (FH). Bempedoic acid, an ATP citrate lyase inhibitor, is an oral medication recently approved that can lower LDL-C by approximately 18% alone and 38% when combined with ezetimibe. Inclisiran, a small-interfering RNA (siRNA) molecule which inhibits the translation of PCSK9, is the most recently FDA-approved LDL-C lowering medication, and can reduce LDL-C by approximately 50% with twice yearly subcutaneous dosing. The cardiovascular outcome trials for bempedoic acid and inclisiran are still on-going. Evinacumab, a monoclonal antibody which targets angiopoietin-like protein 3 (ANGPTL3), has been approved for use in patients with homozygous FH. SiRNAs and anti-sense oligonucleotides (ASO) facilitating selective inhibition of the production of targeted proteins including Lp(a) and ANGLPTL3 are active areas of clinical investigation.</p><p><strong>Summary: </strong>Recently several novel LDL-C lowering medications have been approved. New therapeutic targets have been identified and present additional means of lowering LDL-C and other atherogenic compounds for patients who remain at high ASCVD risk.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 9","pages":"69-78"},"PeriodicalIF":2.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543364/pdf/nihms-1819176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10133436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}